Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: A randomised trial - ANRS HB02 VAC-ADN

Gut

Volumn 64, Issue 1, 2015, Pages 139-146

  Fontaine, H ^a   Kahi, S ^b   Chazallon, C ^b   Bourgine, M ^c   Varaut, A ^d   Buffet, C ^e   Godon, O ^c   Meritet, J F ^f   Saidi Y ^b   Michel, M L ^c   Scott Algara, D ^c   Aboulker, J P ^b   Pol, S ^a  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e BICÊTRE HOSPITAL   (France)

^f Cochin Hospital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; DNA VACCINE; EMTRICITABINE; ENTECAVIR; GAMMA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B VACCINE;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DNA IMMUNIZATION; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEADACHE; HEPATITIS; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE INDURATION; INJECTION SITE PAIN; LIMIT OF DETECTION; LIVER CELL CARCINOMA; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RISK REDUCTION; SEROCONVERSION; T LYMPHOCYTE; TREATMENT DURATION; TUMOR ABLATION; VIRAL PHENOMENA AND FUNCTIONS; VIRAL SUPPRESSION; VIREMIA; VIRUS REACTIVATION; CLINICAL TRIAL; HEPATITIS B, CHRONIC; MIDDLE AGED; RECURRENT DISEASE; TREATMENT FAILURE;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT FAILURE; VACCINES, DNA;

EID: 84919773476     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305707     Document Type: Article

References (43)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73 e1261.
2. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
3. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-10.
4. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
5. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
6. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
7. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
8. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
9. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
10. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-82.
11. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-608. e1591-1592.
12. Liver, EAFTSOT. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
13. Bertoletti A, Ferrari C. Innate and adaptative immune response in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61: 1754-64.
14. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
15. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
16. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
17. Michel ML, Mancini-Bourgine M. Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 2005; 34(SUPPL. 1):S108-14.
18. Pol S, Driss F, Michel M-L, et al. Specific vaccine therapy in chronic hepatitis B infection [letter]. Lancet 1994; 344: 342.
19. Couillin I, Pol S, Mancini M, et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999; 180: 15-26.
20. Pol S, Nalpas B, Driss F, et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001; 34: 917-21.
21. Mancini-Bourgine M, Fontaine H, Brechot C, et al. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 2006; 24: 4482-9.
22. Mancini-Bourgine M, Fontaine H, Scott-Algara D, et al. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40: 874-82.
23. Scott-Algara D, Mancini-Bourgine M, Fontaine H, et al. Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination. PLoS ONE 2010; 5:e8761.
24. ∗0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J Immunol 2000; 165: 4748-55.
25. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963-71.
26. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011; 54: 1286-96.
27. Petrelli E, Balducci M, Pieretti C, et al. Lamivudine treatment failure in preventing fatal outcome of de novo severe acute hepatitis B in patients with haematological diseases. J Hepatol 2001; 35: 823-6.
28. Fontana RJ Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49:S185-95.
29. Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with Adefovir. Gastroenterology 2012; 143: 629-36 e621.
30. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
31. Hoa PT, Huy NT, Thu le T, et al. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother 2009; 53: 5134-40.
32. Wang XY, Zhang XX, Yao X, et al. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine 2010; 28: 8169-74.
33. Vandepapeliere P, Lau GK, Lerox-Roels G, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007; 25: 8585-97.
34. Pancholi P, Lee DH, Liu Q, et al DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 2001; 33: 448-54.
35. Lu M, Hilken G, Kruppenbacher J, et al. Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J Virol 1999; 73: 281-9.
36. Davis HL, McCluskie MJ, Gerin JL, et al. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 1996; 93: 7213-18.
37. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
38. Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143: 963-73. e969.
39. Fuller MJ, Khanolkar A, Tebo AE, et al. Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections. J Immunol 2004; 172: 4204-14.
40. Cavenaugh JS, Awi D, Mendy M, et al. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS ONE 2011; 6:e14626.
41. Yang FQ, Yu YY, Wang GQ, et al. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat 2012; 19: 581-93.
42. Fournillier A, Frelin L, Jacquier E, et al. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. J Infect Dis 2013; 208: 1008-19.
43. Li N, Peng LH, Chen X, et al. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Vaccine 2011; 29: 6179-90.